問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Rheumatology

Division of General Internal Medicine

Taipei Chang Gung Medical Foundation

Division of Rheumatology

更新時間:2023-09-19

蔡秉翰Tsai, Ping-Han
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月
  • s001033@gmail.com

  • s001033@gmail.com

篩選

List

78Cases

2025-11-01 - 2027-10-11

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-08-09 - 2026-08-14

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2019-09-01 - 2024-05-14

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2021-09-10 - 2026-10-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-08-10 - 2025-04-25

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2024-10-04 - 2027-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-12-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-07-31 - 2026-04-30

Phase II/III

Completed
A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout
  • Condition/Disease

    Gout

  • Test Drug

    ABP-671

Participate Sites
4Sites

Recruiting3Sites

Study ended1Sites

2024-09-01 - 2030-10-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-12-01 - 2025-12-31

Phase IV

Active
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population
  • Condition/Disease

    Lupus Nephritis

  • Test Drug

    Myfortic 180 mg、360 mg Gastro-Resistant Tablets

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites